Skip to main content
. 2019 Nov 27;6:268. doi: 10.3389/fmed.2019.00268

Table 6.

Main SPECT and PET cholinergic tracers, molecular structures, pharmacological properties, and examples of clinical studies.

Compounds Imaging modality Target/ measure Affinity (nM) Clinical studies Compounds Imaging modality Target/ measure Affinity (nM) Clinical studies
Inline graphic
[11C]-PMP		 TEP AChE activity NA AD (237, 239, 240, 259), PD (239) Inline graphic
[123I]-5IA		 SPECT α4β2 nAChR density Kd = 0.011 in rats (260) AD (252)
Inline graphic
[11C]-MP4A		 TEP AChE activity NA AD (242), PD (238, 241), LBD (261), PSP (238) Inline graphic
[18F]-2FA		 TEP α4β2 nAChR density Ki = 0.046 in rats (262) AD (253)
Inline graphic
[123I]-IBVM		 SPECT VAChT density IC50 = 2.5 ± 0.2 in rats (263) MSA (245) Inline graphic
[123I]-QNB		 SPECT mAChR density IC50 = 0.8 in mouse (264) AD (265), PD, LBD (258)
Inline graphic
[18F]-FEOBV		 TEP VAChT density AD (266), LBD (246) Inline graphic
[11C]-NMPB		 TEP mAChR density IC50 = 1.8 in mouse (264) AD (267), PD, PSP (257)
Inline graphic
[11C]-nicotine		 TEP α4β2 nAChR density Kd = 2.4 in rats (268) AD (248–250) Inline graphic
[18F]-ASEM		 TEP α7 nAChR density Ki = 0.3 in HEK293 cells stably transfected with rat α7 nAChR (269) Schizophrenia (270)